drugset / Trial / NCT03061981

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

NCT03061981

Phase 1 Completed 60 enrolled Dong-A ST Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double blind, placebo controlled, single ascending dose study to assess the safety, tolerability, PK, PD and IE with metformin following a single oral dose of DA-1241 in healthy male subjects.

Timeline

Start
2017-03-29
Primary completion
2017-10-11
Completion
2017-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-1241 Unknown Oral
Subject Metformin Small molecule 500 mg Oral